Investigating how blood pressure and cholesterol medications may prevent dementia
The effect of antihypertensive and statin therapy on dementia incidence: a novel analytical approach in large electronic health record datasets with long follow-up times and minimal loss to follow-up
This study is looking at whether certain blood pressure and cholesterol medications can help prevent Alzheimer's and other types of dementia, using health records from many patients to see how well these treatments work over time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10993092 on NIH RePORTER |
What this research studies
This research explores the potential of antihypertensive and statin therapies to prevent Alzheimer's disease and related dementias by analyzing large electronic health record datasets. The study utilizes a novel analytical approach that examines patients' responses to medication based on specific clinical thresholds, allowing for a more accurate assessment of the medications' effects over long follow-up periods. By leveraging data from multiple health systems, the research aims to provide insights that could lead to better prevention strategies for dementia. Patients' medication adherence and health outcomes will be closely monitored to understand the long-term impacts of these therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at risk for Alzheimer's disease who are also receiving antihypertensive or statin medications.
Not a fit: Patients who are not at risk for Alzheimer's disease or who are not on antihypertensive or statin therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved prevention strategies for Alzheimer's disease and related dementias, potentially reducing the incidence of these conditions.
How similar studies have performed: Previous research has shown mixed results regarding the effects of these medications on dementia prevention, making this approach both innovative and necessary to clarify existing uncertainties.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Geldsetzer, Pascal — Stanford University
- Study coordinator: Geldsetzer, Pascal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.